report tazverik sale est continu
expect broad fl approv pdufa cash
reiter runway least slightli rais tazverik est due
good start continu see upsid stock broad approv
take tazverik good launch es despit encourag
tazverik sale well estimate confirm
impact tazverik pdufa
view tazverik high probabl receiv broad approv all-com fl
therebi unlock lucr opportun wt market
mut market view current stock price ezpm indic investor still
given much valu wt segment think risk/reward favor
head fda decis fl given low expect approv wt
see stock trade w/ approv mut w/ broad
think earli uptak tazverik es bode well fl launch expect
impact fl launch still depend quickli situat stabil
whether wave outbreak fall/wint
encourag digit platform compani built virtual engag salesforc
physician help upcom fl launch
earli tazverik alreadi see off-label usag fl
patient w/ tumor note compani fulli fund least
ezpm report tazverik sale assum sale predominantli
es g/n discount suggest least patient therapi last
mo alreadi origin estimate patient therefor
rais sale est es
notabl academ center main prescrib tazverik es
fl patient expect eman commun segment note
commerci launch readi nearli complet fl continu receiv posit
feedback physician expect leverag virtual market capabl
es support fl launch given lack new drug fl believ tazverik
gain traction time
overal think earli adopt encourag tazverik acceler
uptak fl launch
pleas see page report import disclosur
classic turnaround emerg hardship tazverik de-risk asset
fda approv epithelioid sarcoma es consult enthusiast
anticip peak sale make attract overlook opportun tazverik
file dec follicular lymphoma fl high convict tazverik
approv fl mut data bigger wt less robust
still approv given drug meaning efficaci clean safeti profil concern
partial clinic hold due secondari malign patient overdon
address label believ stock offer attract profil given
upsid potenti late stage asset
fda decis fl us
complet safeti evalu tazverik
r/r fl
initi studi tazverik parpi
platinum-resist solid tumor
tazverik reach peak sale
tazverik approv
epitheloid sarcoma fl
wt
tazverik safeti
issu sinc one case malign
transform led prior
tazverik sale reach move
fl
get acquir attract
tazverik approv wt fl
need addit capit
focus epigenet develop small molecul inhibitor
histon methyltransferas hmt play key role regul gene
express tazverik tazemetostat oral small molecul inhibitor well-
character hmt ph ii trial relapsed/refractori nhl ph ii adult ph
pediatr genet defin refractori solid tumor tazverik file fda approv
follicular lymphoma approv epithelioid sarcoma es jan
anticip regulatori decis fl pdufa
continu expect fda approv all-com fl label
compani also reiter plan complet on-going safeti run-in portion
begin efficaci expans portion clinic trial includ
tazverik doxorubicin es tazverik fl
tazverik xtandi/zytiga metastaticcastration-resist prostat cancer mcrpc
manag note number fl patient need enrol small
safeti run-in portion compani also shift virtual way enrol patient
open addit site complet enrol soon possibl
therefor dont anticip major disrupt epzm clinic progress due
cowen compani
epizym quarterli us eu incom incom loss incom tax incom ep option net tax incom ex non-cash stock option ep outstand cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
forecast sale product difficult outlook could alter
competit clinic develop failur reimburs chang new competit
could also impact sale estim pipelin product might fail develop
risk includ clinic develop regulatori price commerci challeng may
prevent financi forecast materi
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock argenx secur
cowen compani llc manag co-manag public offer argenx past month
cowen compani llc receiv compens invest bank servic argenx past month
cowen compani llc and/or affili expect receiv intend seek compens invest bank servic next month argenx
argenx past month client cowen compani llc cowen compani llc provid provid invest bank servic past
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
